DETAILED ACTION
Claims 4, 5, 12, 13, 16, 17, 20-22, 26, 30-34, and 44 are currently pending in the instant application. Claims 4, 12, 13, 17, and 21 are rejected. Claims 5, 16, and 20 are objected. Claims 22, 26, 30-34 and 44 are withdrawn from consideration as being for non-elected subject matter.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6 April 2026 has been entered.
Election/Restrictions
Applicant’s election without traverse of Group I and the species:
PNG
media_image1.png
118
190
media_image1.png
Greyscale
in the reply filed on 21 May 2025 has been previously acknowledged.
According to MPEP 803.02, the examiner has previously determined whether the elected species is allowable. Applicants’ elected species appears allowable. Therefore, the search and examination has been extended to the compounds of claims 5, 16 and 20 which also appear allowable, and further to the compound
PNG
media_image2.png
106
202
media_image2.png
Greyscale
which is not allowable. Claims 4, 5, 12, 13, 16, 17, 20 and 21 have been examined to the extent that they are readable on the elected embodiment, the elected species and the above mentioned compound.
Response to Amendment and Arguments
Applicant's amendment and arguments filed 24 March 2026 have been fully considered and entered into the instant application. As claim 4 is rejected, the objection to claims 16 and 20 for being dependent upon a rejected base claim is maintained. Applicant’s amendment to claim 4 has perfected priority to US Application No. 62/939,263, therefore, the 35 USC 102(a)(2) rejections as being anticipated by Registry No. 2415779-23-4, Registry No. 2415758-96-0, and WO 2022/072741 are overcome.
Claim Objections
Claims 5, 16, and 20 are objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claims.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claim(s) 4, 12, 13, 17, and 21 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by WO 2020/243423, filed 29 May 2020, claiming priority to US Application No. 62/928,931, filed 31 October 2019.
WO 2020/243423 discloses the compound I-60 on page 72:
PNG
media_image3.png
178
268
media_image3.png
Greyscale
Pharmaceutical compositions are disclosed on page 95, which provides conventional carriers on page 96. The compound I-60 corresponds to the formula
PNG
media_image4.png
182
274
media_image4.png
Greyscale
, for example, wherein z11 is 0; R1.4 and R1.5 are each hydrogen; L4 is -NR4-; R4 is hydrogen; R5 is
PNG
media_image5.png
86
112
media_image5.png
Greyscale
; R18, R16, and R17 are each hydrogen; L3 is a unsubstituted alkylene; z2 is 1; and R2 is CX23; wherein X2 is -F. In regards to claim 12, the compound I-60 anticipates instant claim 12 as claim 12 does not limit the formula of claim 4 to
PNG
media_image6.png
122
292
media_image6.png
Greyscale
, but merely further limits the formula
PNG
media_image6.png
122
292
media_image6.png
Greyscale
, however, the formula of claim 12 can still be
PNG
media_image7.png
174
316
media_image7.png
Greyscale
.
US Application No. 62/928,931 discloses the compound I-75 on page 56:
PNG
media_image8.png
146
228
media_image8.png
Greyscale
which provides support for the compound I-60 in WO 2020/243423.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 23 September 2026
Rebecca Anderson
Primary Examiner
Art Unit 1626, Group 1620
Technology Center 1600